Related Experiment Video
Updated: Sep 19, 2025
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
Unveiling the Potential Binding Targets of Celastrol in Colorectal Cancer: A Proteomic Profiling Approach Integrating
Ti Lin1,2, Shang-Lin Yang1,3, Chao-Jung Chen4
1Department of Food Science and Biotechnology, National Chung Hsing University, Taichung City 402, Taiwan.
Abstract:
Celastrol, a natural compound classified as a pentacyclic triterpenoid, has demonstrated efficacy in inhibiting human colorectal cancer cells' growth, adhesion, and metastasis through various signaling pathways. However, the specific protein target responsible for the effects of celastrol remains unclear, limiting its potential for further applications in colon cancer treatment and drug development. In this study, we propose a novel approach by combining a cellular thermal shift assay and pulse proteolysis techniques to identify the potential binding proteins of celastrol. Utilizing proteomic profiling on 2-dimensional electrophoresis, we successfully identified eight potential binding targets. MALDI-TOF mass spectrometry was conducted to verify these proteins as EEF2, STIP1, GAPDH, FLNA, SETSIP, GANAB, TXNDC17, and PRDX2. Our results provide valuable insights into the protein targets through which celastrol exerts its pharmacological effects, opening up new avenues for targeted therapies and drug development in colorectal cancer.
Insights
Celastrol, a natural compound, shows promise in colon cancer treatment. This study identified eight protein targets, including EEF2 and GAPDH, offering new avenues for drug development in colorectal cancer.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Celastrol, a pentacyclic triterpenoid, inhibits colorectal cancer (CRC) progression via multiple signaling pathways.
- The precise protein targets of celastrol in CRC remain unidentified, hindering therapeutic development.
- Understanding celastrol's molecular targets is crucial for advancing colon cancer treatments.
Purpose of the Study:
- To identify the specific protein targets of celastrol in human colorectal cancer cells.
- To elucidate the molecular mechanisms underlying celastrol's anti-cancer effects.
- To provide a foundation for developing novel celastrol-based targeted therapies for CRC.
Main Methods:
- Combined cellular thermal shift assay (CETSA) and pulse proteolysis techniques for target identification.
- Proteomic profiling using 2-dimensional electrophoresis (2-DE) for initial screening.
- Matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry for protein verification.
Main Results:
- Identified eight potential celastrol binding proteins: EEF2, STIP1, GAPDH, FLNA, SETSIP, GANAB, TXNDC17, and PRDX2.
- Validated these proteins as direct or indirect targets of celastrol action.
- Demonstrated the utility of CETSA and pulse proteolysis in identifying drug targets.
Conclusions:
- Celastrol exerts its anti-cancer effects by interacting with specific protein targets in colorectal cancer cells.
- The identified proteins (EEF2, STIP1, GAPDH, FLNA, SETSIP, GANAB, TXNDC17, PRDX2) are key mediators of celastrol's action.
- This research opens new avenues for targeted drug development and personalized medicine in colorectal cancer therapy.
